The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CATB | +9.45% | +55.26% | +9.2% | -98% |
| S&P | +19.61% | +98.99% | +14.75% | +226% |
Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $302.49M | -39.5% |
| Market Cap / Employee | $3.88M | 0.0% |
| Employees | 78 | 32.2% |
| Net Income | -$33.05M | -36.7% |
| EBITDA | -$35.82M | -24.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $76.32M | -12.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $3.37M | -25.9% |
| Short Term Debt | $1.40M | 12.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.98% | -3.6% |
| Return On Invested Capital | -66.54% | 8.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$36.65M | -114.4% |
| Operating Free Cash Flow | -$36.06M | -114.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.40 | 2.05 | 1.35 | 1.56 | -14.97% |
| Price to Tangible Book Value | 2.40 | 2.05 | 1.35 | 1.56 | -14.97% |
| Enterprise Value to EBITDA | -13.55 | -9.36 | -3.11 | -4.24 | -53.09% |
| Return on Equity | -38.0% | -33.5% | -32.9% | -38.5% | 13.00% |
| Total Debt | $5.64M | $5.35M | $5.06M | $4.77M | -17.67% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
